Literature DB >> 22961214

Oligoclonal bands and cerebrospinal fluid markers in multiple sclerosis: associations with disease course and progression.

Pedro Lourenco1, Afsaneh Shirani, Jameelah Saeedi, Joel Oger, William E Schreiber, Helen Tremlett.   

Abstract

BACKGROUND: The use of oligoclonal bands (OCBs) and cerebrospinal fluid (CSF) parameters are established in the diagnosis of MS, but poorly as markers of disease.
OBJECTIVE: To investigate the role of OCBs in disease course and progression.
METHODS: CSF data for 1120 patients with MS were analyzed for associations between OCBs and CSF parameters and clinical data (disease course [relapsing-onset MS (ROMS) vs primary-progressive MS (PPMS)]), disability progression (proportion reaching Expanded Disability Status Scale 6 within 10 years of onset and progression index) and ethnicity.
RESULTS: Of patients with MS, 72.5% had detectable OCBs. For patients with detectable OCBs, 84.6% had ROMS and 15.4% PPMS versus 89.7% and 10.3%, respectively for those without detectable OCBs (p=0.04). Total CSF IgG and protein levels were higher in PPMS compared with ROMS (p<0.001). Disease progression appeared independent of OCB status. Patients with CSF (vs without) data were more likely to be male, older at onset, have PPMS and lack optic neuropathy at onset (p<0.001).
CONCLUSIONS: OCB positivity and elevated total CSF IgG and protein were moderately associated with a PPMS disease course, but not disease progression. Patients with atypical clinical presentations were more likely to have had CSF work-up, suggesting a testing bias.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22961214     DOI: 10.1177/1352458512459684

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  17 in total

Review 1.  The utility of cerebrospinal fluid analysis in patients with multiple sclerosis.

Authors:  Martin Stangel; Sten Fredrikson; Edgar Meinl; Axel Petzold; Olaf Stüve; Hayrettin Tumani
Journal:  Nat Rev Neurol       Date:  2013-03-26       Impact factor: 42.937

Review 2.  The role of melatonin in Multiple Sclerosis.

Authors:  Charalampos Skarlis; Maria Anagnostouli
Journal:  Neurol Sci       Date:  2019-12-16       Impact factor: 3.307

Review 3.  Body fluid biomarkers in multiple sclerosis: how far we have come and how they could affect the clinic now and in the future.

Authors:  Itay Raphael; Johanna Webb; Olaf Stuve; William Haskins; Thomas Forsthuber
Journal:  Expert Rev Clin Immunol       Date:  2014-12-18       Impact factor: 4.473

Review 4.  The Multiple Roles of B Cells in Multiple Sclerosis and Their Implications in Multiple Sclerosis Therapies.

Authors:  Rui Li; Amit Bar-Or
Journal:  Cold Spring Harb Perspect Med       Date:  2019-04-01       Impact factor: 6.915

Review 5.  Breaching Brain Barriers: B Cell Migration in Multiple Sclerosis.

Authors:  Carla Rodriguez-Mogeda; Sabela Rodríguez-Lorenzo; Jiji Attia; Jack van Horssen; Maarten E Witte; Helga E de Vries
Journal:  Biomolecules       Date:  2022-06-07

6.  HLA class I & II alleles in multiple sclerosis patients from Puerto Rico.

Authors:  María T Miranda; Erick Suárez; Muneer Abbas; Angel Chinea; Rafael Tosado; Ida A Mejías; Nawal Boukli; Georgia M Dunston
Journal:  Bol Asoc Med P R       Date:  2013

7.  No prognostic value of routine cerebrospinal fluid biomarkers in a population-based cohort of 407 multiple sclerosis patients.

Authors:  Madlyne Becker; Clotilde Latarche; Emilie Roman; Marc Debouverie; Catherine Malaplate-Armand; Francis Guillemin
Journal:  BMC Neurol       Date:  2015-05-13       Impact factor: 2.474

8.  Oligoclonal Bands in Cerebrospinal Fluid of Black Patients with Multiple Sclerosis.

Authors:  Paulo Diniz da Gama; Luís dos Ramos Machado; José Antonio Livramento; Hélio Rodrigues Gomes; Tarso Adoni; Rogério de Rizo Morales; Rodrigo Assad Diniz da Gama; Daniel Assad Diniz da Gama; Marco Aurélio Lana-Peixoto; Yara Dadalti Fragoso; Dagoberto Callegaro
Journal:  Biomed Res Int       Date:  2015-07-29       Impact factor: 3.411

9.  UK multiple sclerosis risk-sharing scheme: a new natural history dataset and an improved Markov model.

Authors:  Jacqueline Palace; Thomas Bregenzer; Helen Tremlett; Joel Oger; Feng Zhu; Fheng Zhu; Mike Boggild; Martin Duddy; Charles Dobson
Journal:  BMJ Open       Date:  2014-01-17       Impact factor: 2.692

10.  Oligoclonal band status in Scandinavian multiple sclerosis patients is associated with specific genetic risk alleles.

Authors:  Inger-Lise Mero; Marte W Gustavsen; Hanne S Sæther; Siri T Flåm; Pål Berg-Hansen; Helle B Søndergaard; Poul Erik H Jensen; Tone Berge; Anja Bjølgerud; Aslaug Muggerud; Jan H Aarseth; Kjell-Morten Myhr; Elisabeth G Celius; Finn Sellebjerg; Jan Hillert; Lars Alfredsson; Tomas Olsson; Annette Bang Oturai; Ingrid Kockum; Benedicte A Lie; Bettina Kulle Andreassen; Hanne F Harbo
Journal:  PLoS One       Date:  2013-03-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.